# Thermo Fisher Scientific Inc.: Form 10-K for the period ended Dec 31, 2025

- Company: [Thermo Fisher Scientific Inc.](/companies/tmo.md) (CIK 97745)
- Form: 10-K
- Filed: 2026-02-26
- Accepted by EDGAR: Feb 26, 2026, 12:11 ET
- Period: 2025-12-31
- Accession: 0000097745-26-000018
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/97745/000009774526000018/tmo-20251231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/97745/000009774526000018/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2025-01-01 to 2025-12-31 | $44.56bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 12 months, 2025-01-01 to 2025-12-31 | $1.40bn | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months, 2025-01-01 to 2025-12-31 | $8.73bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months, 2025-01-01 to 2025-12-31 | $7.75bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2025-01-01 to 2025-12-31 | $1.42bn | us-gaap:InterestExpenseNonoperating |
| Income tax | 12 months, 2025-01-01 to 2025-12-31 | $547.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2025-01-01 to 2025-12-31 | $6.70bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2025-01-01 to 2025-12-31 | $17.74 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2025-01-01 to 2025-12-31 | $17.77 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2025-01-01 to 2025-12-31 | 378,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2025-01-01 to 2025-12-31 | $7.82bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2025-01-01 to 2025-12-31 | $1.52bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months, 2025-01-01 to 2025-12-31 | $636.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 12 months, 2025-01-01 to 2025-12-31 | $3.00bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2025-12-31 | $9.85bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2025-12-31 | $28.71bn | us-gaap:AssetsCurrent |
| Total assets | at 2025-12-31 | $110.34bn | us-gaap:Assets |
| Current liabilities | at 2025-12-31 | $15.19bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2025-12-31 | $39.17bn | us-gaap:LongTermDebt |
| Current portion of debt | at 2025-12-31 | $3.53bn | us-gaap:DebtCurrent |
| Shareholders' equity | at 2025-12-31 | $53.41bn | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/97745/000009774526000018/tmo-20251231.htm

Filed Feb 26, 2026.
Source: SEC EDGAR, the filing index for accession 0000097745-26-000018. Last ingested by Listed: Nov 14, 2026, 12:05 ET. No prices; not investment advice.
